Piramal Pharma Limited Expands Biologics Manufacturing Capabilities to Enhance Integrated Drug Development Solutions

Piramal Pharma Limited is expanding its capabilities in biologics manufacturing to address increasing demand for integrated drug development solutions. Peter DeYoung, the company’s CEO, outlined the efforts being made to enhance expertise and infrastructure in this area. The initiative aims to streamline processes from discovery through delivery, ensuring efficient production and development of biologic drugs.

The company is focusing on strengthening its end-to-end services by investing in advanced technologies and specialized facilities. This expansion includes bolstering its capacity for biologics manufacturing, which involves producing complex medicines derived from living organisms. Piramal Pharma Limited seeks to meet industry needs by offering comprehensive solutions that integrate research, development, and manufacturing under one roof.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 30, 2025

Related posts:

FDA Preserves Drug Review Staffing, but Review Process May Still Face Impacts Digital Tools Like ePRO and eCOA Replace Paper Methods in Clinical Trials for Real-Time Data Collection PDSA Cycle Implementation in Retail Pharmacies Boosts 20-Valent Pneumococcal Vaccine Uptake Among Eligible Adults Lawmakers Lobby Physician Groups Over Medicaid Cuts in Trump Tax Bill

Author

Mark Chiang